Barclays
ACER

Barclays’s Acer Therapeutics Inc ACER Stock Holding History

Barclays’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,737
Closed -$24K – 5134
2021
Q1 		$24K Sell
7,737
-47,320
-86% -$161K ﹤0.01% 4341
2020
Q4 		$144K Sell
55,057
-545
-1% -$1.47K ﹤0.01% 3959
2020
Q3 		$160K Sell
55,602
-38,971
-41% -$126K ﹤0.01% 3990
2020
Q2 		$324K Sell
94,573
-227
-0.2% -$641 ﹤0.01% 3682
2020
Q1 		$188K Sell
94,800
-3,356
-3% -$12.3K ﹤0.01% 4348
2019
Q4 		$393K Buy
98,156
+2,502
+3% +$8.5K ﹤0.01% 4500
2019
Q3 		$305K Buy
95,654
+49,023
+105% +$144K ﹤0.01% 4650
2019
Q2 		$182K Buy
46,631
+2,135
+5% +$40.7K ﹤0.01% 5202
2019
Q1 		$1.08M Buy
44,496
+19,696
+79% +$465K ﹤0.01% 3320
2018
Q4 		$499K Buy
+24,800
New +$571K ﹤0.01% 3824
2013
Q3 		– Sell
-79
Closed -$10K – 7660
2013
Q2 		$10K Buy
+79
New +$11.5K ﹤0.01% 7144

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Barclays's ACER Position: Q2 2021 in Review

Barclays sold out of Acer Therapeutics Inc (ACER) in Q2 2021, closing a stake of 7,737 shares — an estimated $24K sold.

Barclays first reported a position in ACER in Q2 2013 and held it in 11 quarters. The position peaked at $1.08M in Q1 2019. 30 funds tracked by Wall St. Rank hold ACER as of Q2 2021.

  • Barclays reported no remaining Acer Therapeutics Inc position as of Q2 2021 after selling out during the quarter.
  • Barclays sold 7,737 Acer Therapeutics Inc shares in Q2 2021, an estimated $24K.
  • Barclays first reported a position in Acer Therapeutics Inc in Q2 2013 and held it in 11 quarters.
  • Barclays's Acer Therapeutics Inc position peaked at $1.08M in Q1 2019.
  • 30 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q2 2021.

Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.